We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biosenic Sa | LSE:0R55 | London | Ordinary Share | BE0974280126 | BIOSENIC ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.845 | 3.75 | 3.94 | 33,856 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 316k | -2.04M | -0.0168 | -1.19 | 2.44M |
REGULATED INFORMATION
The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail.
The BioSenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of chronic Graft versus Host disease (cGvHD) has been completed and provided positive results. In 2024, the BioSenic Group expects to prioritize the use of the proceeds of anticipated future fundraising for the progression of the Phase 3 clinical trial in cGvHD. |
Mont-Saint-Guibert, Belgium, 7 September 2023, 7am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today publishes its business update for the first half, ended 30 June 2023, prepared in accordance with IFRS as adopted by the European Union, and the outlook for the remainder of the year.
"BioSenic has made the best of its efforts on restructuring and accomplishing important technical steps in implementing key features of its Arsenic salts (ATO) and its cell repair platforms after succeeding its reverse merger between Medsenic and Bone Therapeutics 10 months ago” said François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic “Successfully interpreting clinical and scientific complex data – and specifically those inherited from the former Bone Therapeutics – gives us now the essential basic elements to develop our activities on licensing opportunities and further Phase 2/3 clinical trials. Our immediate leading project is a Phase 3 confirmatory trial on the efficacy of an oral formulation of arsenic trioxide on chronic Graft-versus-Host Disease, an autoimmune rare condition following allogeneic hematopoietic cells used for treating several types of leukaemia. We now expect a productive end of 2023 for further developing the best values of BioSenic."
Operational and Corporate highlights
Financial highlights
Outlook for the remainder of 2023 and 2024
Unaudited Interim Condensed Consolidated Statement of Comprehensive Income
(in thousands of euros) | For the six-months period ended | |
30/06/2023 | 30/06/2022 | |
Revenues | 0 | 0 |
Other operating income | 365 | 125 |
Total revenues and operating income | 365 | 125 |
Research and development expenses | (2,452) | (267) |
General and administrative expenses | (1,813) | (336) |
Other operating expenses | (1) | 0 |
Operating profit/(loss) | (3,900) | (478) |
Financial Income | 35 | 0 |
Interest income | 30 | 0 |
Impairment expenses | (16,094) | 0 |
Financial expenses | (1,136) | (49) |
Exchange gains/(losses) | 1 | 0 |
Result Profit/(loss) before taxes | (21,063) | (527) |
Income taxes | (24) | - |
Result Profit/(loss) for the Period | (21,087) | (527) |
Thereof attributable to: | ||
Owners of the Company | (20,843) | (527) |
Non-controlling interests | (244) | 0 |
Other comprehensive income | 0 | 0 |
TOTAL COMPREHENSIVE INCOME/(LOSS) OF THE PERIOD | (21,087) | (527) |
Thereof attributable to: | ||
Owners of the Company | (20,843) | (527) |
Non-controlling interests | (244) | 0 |
Basic and diluted loss per share (in euros) | (0,17) | (7,49) |
Unaudited Interim Condensed Consolidated Statement of Financial Position
Consolidated Assets IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 | |
Non-current assetsGoodwill | 7,8480 | 24,6981,802 | |
Intangible assets | 2,995 | 17,293 | |
Property, plant and equipment | 786 | 1,419 | |
Finance lease receivable | 469 | 0 | |
Investments in associates | 12 | 12 | |
Other non-current assets | 135 | 136 | |
R&D Tax Credits | 3,452 | 4,036 | |
Current assets | 2,544 | 4,626 | |
Trade and other receivables | 1,676 | 2,490 | |
Other current assets | 214 | 290 | |
Finance lease receivable | 135 | 0 | |
Cash and cash equivalents | 519 | 1,846 | |
TOTAL ASSETS | 10,392 | 29,324 |
Consolidated Equity & Liabilities IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 | |
Equity attributable to owners of the parent | (16,882) | 3,526 | |
Share capital | 5,224 | 4,774 | |
Share premium | 4,594 | 4,517 | |
Accumulated losses and other reserves | (26,652) | (5,723) | |
Other reserves | (48) | (42) | |
Equity attributable to owners of the parent | |||
Non-controlling interests | (646) | (402) | |
Total Equity | (17,528) | 3,124 | |
Non-current liabilities | 15,764 | 15,847 | |
Interest bearing borrowings | 15,696 | 15,779 | |
Other non-current liabilities | 68 | 68 | |
Current liabilities | 12,156 | 10,353 | |
Interest bearing borrowings | 9,339 | 8,013 | |
Trade and other payables | 2,728 | 2,236 | |
Other current liabilities | 89 | 104 | |
Total liabilities | 27,920 | 26,200 | |
TOTAL EQUITY AND LIABILITIES | 10,392 | 29,324 |
Unaudited Interim Condensed Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows (in thousands of euros) | For the six-month period ended 30 June | |
2023 | 2022 | |
CASH FLOW FROM OPERATING ACTIVITIES | ||
Operating profit/(loss) | (3,900) | (478) |
Adjustments for: | ||
Depreciation and Amortisation | 101 | 5 |
Grants income related to tax credit | (115) | 0 |
Grants income related to withholding tax | (47) | |
Other | (68) | 0 |
Movements in working capital: | ||
(Increase)/Decrease in Trade and other receivables (excluding government grants) | (34) | 14 |
Increase/(Decrease) in Trade and other Payables | 492 | 22 |
Cash used by operations | (3,570) | (438) |
Cash received from license agreement | 940 | 0 |
Cash received from grants related to tax credit | 700 | 187 |
Net cash used in operating activities | (1,930) | (251) |
CASH FLOW FROM INVESTING ACTIVITIES | ||
Disposal of intangible assets | 17 | 0 |
Disposal of property, plant and equipment | 3 | 0 |
Purchases of property, plant and equipment | (12) | 0 |
Purchases of intangible assets | (1) | 0 |
Net cash generated from investing activities | 7 | 0 |
CASH FLOW FROM FINANCING ACTIVITIES | ||
Repayment of borrowings | (150) | (45) |
Proceeds from convertible borrowings | 550 | 0 |
Repayment of lease liabilities | (84) | (2) |
Repayment of other financial liabilities | (75) | (75) |
Interests paid | (13) | (16) |
Transaction costs | (81) | |
Proceeds from issue of equity instruments | 450 | 0 |
Net cash generated from financing activities | 596 | (137) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,327) | (388) |
CASH AND CASH EQUIVALENTS at beginning of the period | 1,846 | 759 |
CASH AND CASH EQUIVALENTS at end of the period | 519 | 371 |
Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
Attributable to owners of the parent | Non-controlling interests | TOTAL EQUITY | ||||
(in thousands of euros) | Share capital | Share premium | Accumulated Losses & other reserves | Other elements of comprehensive income | ||
BALANCE AT 1 JANUARY 2022 | 664 | 3,969 | (7,298) | (5) | 0 | (2,670) |
Total comprehensive income of the period | 0 | 0 | (527) | 0 | 0 | (527) |
Issue of share capital | 74 | 3,837 | 0 | 0 | 0 | 3,911 |
BALANCE AT 30 JUNE 2022 | 738 | 7,806 | (7,825) | (5) | 0 | 714 |
BALANCE AT 1 JANUARY 2023 | 4,774 | 4,517 | (5,723) | (42) | (402) | 3,124 |
Total comprehensive income of the period | 0 | 0 | (20,843) | 0 | (244) | (21,087) |
Issue of share capital | 450 | 158 | 0 | 0 | 0 | 609 |
Transaction costs for equity issue | 0 | (81) | 0 | 0 | 0 | (81) |
Other | 0 | 0 | (85) | (6) | 0 | (91) |
BALANCE AT 30 JUNE 2023 | 5,224 | 4,594 | (26,652) | (48) | (646) | (17,528) |
About BioSenicThe interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Biosenic in the section ‘Financial reports’. BioSenic publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original French version will prevail.
BioSenic reports half year 2023 results
The BioSenic Phase 2 clinical study with arsenic trioxide in the first-line treatment of chronic Graft versus Host disease (cGvHD) has been completed and provided positive results. In 2024, the BioSenic Group expects to prioritize the use of the proceeds of anticipated future fundraising for the progression of the Phase 3 clinical trial in cGvHD. |
Mont-Saint-Guibert, Belgium, 7 September 2023, 7am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today publishes its business update for the first half, ended 30 June 2023, prepared in accordance with IFRS as adopted by the European Union, and the outlook for the remainder of the year.
"BioSenic has made the best of its efforts on restructuring and accomplishing important technical steps in implementing key features of its Arsenic salts (ATO) and its cell repair platforms after succeeding its reverse merger between Medsenic and Bone Therapeutics 10 months ago” said François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic “Successfully interpreting clinical and scientific complex data – and specifically those inherited from the former Bone Therapeutics – gives us now the essential basic elements to develop our activities on licensing opportunities and further Phase 2/3 clinical trials. Our immediate leading project is a Phase 3 confirmatory trial on the efficacy of an oral formulation of arsenic trioxide on chronic Graft-versus-Host Disease, an autoimmune rare condition following allogeneic hematopoietic cells used for treating several types of leukaemia. We now expect a productive end of 2023 for further developing the best values of BioSenic."
Operational and Corporate highlights
Financial highlights
Outlook for the remainder of 2023 and 2024
Unaudited Interim Condensed Consolidated Statement of Comprehensive Income
(in thousands of euros) | For the six-months period ended | |
30/06/2023 | 30/06/2022 | |
Revenues | 0 | 0 |
Other operating income | 365 | 125 |
Total revenues and operating income | 365 | 125 |
Research and development expenses | (2,452) | (267) |
General and administrative expenses | (1,813) | (336) |
Other operating expenses | (1) | 0 |
Operating profit/(loss) | (3,900) | (478) |
Financial Income | 35 | 0 |
Interest income | 30 | 0 |
Impairment expenses | (16,094) | 0 |
Financial expenses | (1,136) | (49) |
Exchange gains/(losses) | 1 | 0 |
Result Profit/(loss) before taxes | (21,063) | (527) |
Income taxes | (24) | - |
Result Profit/(loss) for the Period | (21,087) | (527) |
Thereof attributable to: | ||
Owners of the Company | (20,843) | (527) |
Non-controlling interests | (244) | 0 |
Other comprehensive income | 0 | 0 |
TOTAL COMPREHENSIVE INCOME/(LOSS) OF THE PERIOD | (21,087) | (527) |
Thereof attributable to: | ||
Owners of the Company | (20,843) | (527) |
Non-controlling interests | (244) | 0 |
Basic and diluted loss per share (in euros) | (0,17) | (7,49) |
Unaudited Interim Condensed Consolidated Statement of Financial Position
Consolidated Assets IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 |
Non-current assetsGoodwill | 7,8480 | 24,6981,802 |
Intangible assets | 2,995 | 17,293 |
Property, plant and equipment | 786 | 1,419 |
Finance lease receivable | 469 | 0 |
Investments in associates | 12 | 12 |
Other non-current assets | 135 | 136 |
R&D Tax Credits | 3,452 | 4,036 |
Current assets | 2,544 | 4,626 |
Trade and other receivables | 1,676 | 2,490 |
Other current assets | 214 | 290 |
Finance lease receivable | 135 | 0 |
Cash and cash equivalents | 519 | 1,846 |
TOTAL ASSETS | 10,392 | 29,324 |
Consolidated Equity & Liabilities IFRS per: (in thousands of euros) | 30/06/2023 | 31/12/2022 |
Equity attributable to owners of the parent | (16,882) | 3,526 |
Share capital | 5,224 | 4,774 |
Share premium | 4,594 | 4,517 |
Accumulated losses and other reserves | (26,652) | (5,723) |
Other reserves | (48) | (42) |
Equity attributable to owners of the parent | ||
Non-controlling interests | (646) | (402) |
Total Equity | (17,528) | 3,124 |
Non-current liabilities | 15,764 | 15,847 |
Interest bearing borrowings | 15,696 | 15,779 |
Other non-current liabilities | 68 | 68 |
Current liabilities | 12,156 | 10,353 |
Interest bearing borrowings | 9,339 | 8,013 |
Trade and other payables | 2,728 | 2,236 |
Other current liabilities | 89 | 104 |
Total liabilities | 27,920 | 26,200 |
TOTAL EQUITY AND LIABILITIES | 10,392 | 29,324 |
Unaudited Interim Condensed Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows(in thousands of euros) | For the six-month period ended 30 June | |
2023 | 2022 | |
CASH FLOW FROM OPERATING ACTIVITIES | ||
Operating profit/(loss) | (3,900) | (478) |
Adjustments for: | ||
Depreciation and Amortisation | 101 | 5 |
Grants income related to tax credit | (115) | 0 |
Grants income related to withholding tax | (47) | |
Other | (68) | 0 |
Movements in working capital: | ||
(Increase)/Decrease in Trade and other receivables (excluding government grants) | (34) | 14 |
Increase/(Decrease) in Trade and other Payables | 492 | 22 |
Cash used by operations | (3,570) | (438) |
Cash received from license agreement | 940 | 0 |
Cash received from grants related to tax credit | 700 | 187 |
Net cash used in operating activities | (1,930) | (251) |
CASH FLOW FROM INVESTING ACTIVITIES | ||
Disposal of intangible assets | 17 | 0 |
Disposal of property, plant and equipment | 3 | 0 |
Purchases of property, plant and equipment | (12) | 0 |
Purchases of intangible assets | (1) | 0 |
Net cash generated from investing activities | 7 | 0 |
CASH FLOW FROM FINANCING ACTIVITIES | ||
Repayment of borrowings | (150) | (45) |
Proceeds from convertible borrowings | 550 | 0 |
Repayment of lease liabilities | (84) | (2) |
Repayment of other financial liabilities | (75) | (75) |
Interests paid | (13) | (16) |
Transaction costs | (81) | |
Proceeds from issue of equity instruments | 450 | 0 |
Net cash generated from financing activities | 596 | (137) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | (1,327) | (388) |
CASH AND CASH EQUIVALENTS at beginning of the period | 1,846 | 759 |
CASH AND CASH EQUIVALENTS at end of the period | 519 | 371 |
Unaudited Interim Condensed Consolidated Statement of Changes in Shareholders' Equity
Attributable to owners of the parent | Non-controlling interests | TOTAL EQUITY | ||||
(in thousands of euros) | Share capital | Share premium | Accumulated Losses & other reserves | Other elements of comprehensive income | ||
BALANCE AT 1 JANUARY 2022 | 664 | 3,969 | (7,298) | (5) | 0 | (2,670) |
Total comprehensive income of the period | 0 | 0 | (527) | 0 | 0 | (527) |
Issue of share capital | 74 | 3,837 | 0 | 0 | 0 | 3,911 |
BALANCE AT 30 JUNE 2022 | 738 | 7,806 | (7,825) | (5) | 0 | 714 |
BALANCE AT 1 JANUARY 2023 | 4,774 | 4,517 | (5,723) | (42) | (402) | 3,124 |
Total comprehensive income of the period | 0 | 0 | (20,843) | 0 | (244) | (21,087) |
Issue of share capital | 450 | 158 | 0 | 0 | 0 | 609 |
Transaction costs for equity issue | 0 | (81) | 0 | 0 | 0 | (81) |
Other | 0 | 0 | (85) | (6) | 0 | (91) |
BALANCE AT 30 JUNE 2023 | 5,224 | 4,594 | (26,652) | (48) | (646) | (17,528) |
About BioSenic
BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in orthopedics.
Following a reverse merger in October 2022, BioSenic combined a strategic positionings and strengths to use, separately and combined, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.
About BioSenic technology platforms
BioSenic’s technology is based on two main platforms:
1) The ATO platform, which has been successfully developed, has immunomodulatory properties with fundamental effects on the activated cells of the immune system. The first effect is the increase of the cell oxidative stress in activated B, T and other cells of the innate/adaptative immune system to the point they will enter a cell death program (apoptosis) and be eliminated. The second effect is potent immunomodulatory properties on several cytokines involved in inflammatory or autoimmune cell pathways, with return to homeostasis. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT). cGvHD is primarily mediated by the transplanted immune cells that can lead to severe multiorgan damage. BioSenic has been successful in a Phase 2 trial with its intravenous formulation, which has orphan drug designation status by FDA and EMA. The Company is heading towards an international Phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae and the gastrointestinal tract) in an early Phase 2a study. Systemic sclerosis is also part of the clinical pipeline of BioSenic. This serious chronic disease badly affects skin, lungs or vascularization, and has no actual current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a Phase 2 clinical protocol. 2) The allogeneic cell and gene therapy platform developed by BioSenic, with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs), which can be stored at the point of use in hospitals. ALLOB represents a unique and proprietary approach to organ repair and specifically to bone regeneration, by turning undifferentiated stromal cells from healthy donors into bone-forming cells on the site of injury. ALLOB has recently been evaluated in a randomized, double-blind, placebo-controlled Phase 2b study in patients with high-risk tibial fractures, using its optimized production process, after a successful first safety and efficacy study (Phase 1/2a) on fractured long bones, with late-delayed union. However, in June 2023, BioSenic decided to suspend its interventional trial on fracture healing using ALLOB, following negative results obtained for the primary endpoint in this exploratory Phase 2b clinical trial, interpreted as a failure of a too early cell injection, just after fracture. BioSenic is now focusing on determining the best time to optimise the efficacy of ALLOB (choice between early or late treatment).Note: Biosenic has reevaluated a previous important and years-long clinical development program. In March 2023, after the clinical identification of distinct OA subtypes, BioSenic delivered a new post-hoc analysis of its Phase 3 JTA-004 trial on knee OA, demonstrating positive action on the most severely affected patient subpopulation. This new post-hoc analysis drastically changes the therapeutic profile of the combined components and allows for better patient targeting in future clinical developments. This leads to a next generation of JTA, off-the-shelf enhanced viscosupplement to treat knee osteoarthritis (OA), made of a unique combination of mammalian plasma proteins, derivatives of hyaluronic acid (a natural component of synovial fluid in the knee) and a third active component. JTA or some derivatives are intended to provide effective lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic (OA) pain and inflammation. The company, will nevertheless focus its present R&D and clinical activities on a selective, accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please contact:
BioSenic SAFrançois Rieger, PhD, Chief Executive OfficerTel: +33 (0)671 73 31 59investorrelations@biosenic.com
International Media Enquiries:IB CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11 22ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in orthopedics.
Following a reverse merger in October 2022, BioSenic combined a strategic positionings and strengths to use, separately and combined, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.
About BioSenic technology platforms
BioSenic’s technology is based on two main platforms:
Note: Biosenic has reevaluated a previous important and years-long clinical development program. In March 2023, after the clinical identification of distinct OA subtypes, BioSenic delivered a new post-hoc analysis of its Phase 3 JTA-004 trial on knee OA, demonstrating positive action on the most severely affected patient subpopulation. This new post-hoc analysis drastically changes the therapeutic profile of the combined components and allows for better patient targeting in future clinical developments. This leads to a next generation of JTA, off-the-shelf enhanced viscosupplement to treat knee osteoarthritis (OA), made of a unique combination of mammalian plasma proteins, derivatives of hyaluronic acid (a natural component of synovial fluid in the knee) and a third active component. JTA or some derivatives are intended to provide effective lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic (OA) pain and inflammation. The company, will nevertheless focus its present R&D and clinical activities on a selective, accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please contact:
BioSenic SAFrançois Rieger, PhD, Chief Executive OfficerTel: +33 (0)671 73 31 59investorrelations@biosenic.com
International Media Enquiries:IB CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11 22ggasparetto@actifin.fr
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
1 Year Biosenic Chart |
1 Month Biosenic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions